TD Cowen Raises BioNTech (NASDAQ:BNTX) Price Target to $98.00

BioNTech (NASDAQ:BNTX) had its price objective lifted by TD Cowen from $95.00 to $98.00 in a report published on Tuesday, Benzinga reports. The brokerage currently has a hold rating on the stock.

Several other research firms have also recently weighed in on BNTX. BMO Capital Markets cut their target price on BioNTech from $123.00 to $122.00 and set an outperform rating for the company in a research note on Tuesday. UBS Group reduced their price objective on BioNTech from $110.00 to $101.00 and set a neutral rating on the stock in a research note on Wednesday, March 27th. The Goldman Sachs Group decreased their target price on BioNTech from $113.00 to $100.00 and set a neutral rating on the stock in a research report on Wednesday, February 28th. HC Wainwright reissued a buy rating and issued a $107.00 target price on shares of BioNTech in a report on Wednesday, April 17th. Finally, Canaccord Genuity Group reaffirmed a buy rating and set a $171.00 price target on shares of BioNTech in a report on Thursday, March 21st. One research analyst has rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of Hold and a consensus target price of $118.82.

BioNTech Price Performance

Shares of NASDAQ BNTX opened at $92.06 on Tuesday. The stock has a market capitalization of $21.89 billion, a PE ratio of 22.34 and a beta of 0.25. BioNTech has a fifty-two week low of $85.21 and a fifty-two week high of $125.83. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.43 and a quick ratio of 9.26. The business has a fifty day moving average price of $90.53 and a two-hundred day moving average price of $95.92.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 earnings per share for the quarter, missing the consensus estimate of $2.64 by ($0.59). The firm had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $2.04 billion. BioNTech had a return on equity of 4.60% and a net margin of 24.26%. As a group, equities analysts predict that BioNTech will post -1.74 earnings per share for the current fiscal year.

Institutional Trading of BioNTech

A number of hedge funds and other institutional investors have recently made changes to their positions in BNTX. Harding Loevner LP purchased a new position in BioNTech during the 4th quarter valued at about $410,984,000. Baillie Gifford & Co. increased its holdings in BioNTech by 15.5% during the 3rd quarter. Baillie Gifford & Co. now owns 8,602,839 shares of the company’s stock worth $934,612,000 after acquiring an additional 1,152,541 shares during the period. Clearbridge Investments LLC lifted its stake in BioNTech by 41.6% in the 3rd quarter. Clearbridge Investments LLC now owns 484,126 shares of the company’s stock worth $52,595,000 after purchasing an additional 142,344 shares in the last quarter. Primecap Management Co. CA boosted its holdings in BioNTech by 2.8% in the 4th quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock valued at $502,735,000 after purchasing an additional 131,490 shares during the period. Finally, DekaBank Deutsche Girozentrale grew its position in shares of BioNTech by 43.1% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 425,071 shares of the company’s stock valued at $44,610,000 after purchasing an additional 127,951 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.